vatalanib has been researched along with canertinib dihydrochloride in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 31 | 13 | 6 |
| Protein | Taxonomy | vatalanib (IC50) | canertinib dihydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0036 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0132 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.029 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for vatalanib and canertinib dihydrochloride
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |